The decline of miRNA-29a levels in brain has been reported among AD patients, which increases the BACE1 gene expression, itself a risk factor for Alzheimer, making miRNA-29a a promising biomarker for AD. The gene discussed is BACE1; the disease is Alzheimer disease.